Factor VIII-Guided Xa Inhibitor Dosing for Bleeding Risk Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment with direct oral anticoagulants (DOACs), particularly Factor Xa inhibitors, faces challenges in managing bleeding events due to the lack of specific antidotes and the need for assessing coagulation status, especially in cases of major bleeding, trauma, or overdose, necessitating improved dosage optimization.
Innovation Solution
A method for determining Factor Xa inhibitor dosage based on the detection of Factor VIII levels in a subject's blood plasma, using ELISA, one-stage clotting, or chromogenic assays, to prescribe appropriate doses between 0.01-20 mg or 5-50 mg daily, depending on Factor VIII concentrations below or above 100% of standard plasma levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If fixed dosages of factor xa inhibitor are used, then simplicity of administration is maintained, but therapeutic efficacy is reduced for patients with severe factor xa deficiency
Solution Approach 1:
The patent changes the dosage parameter from a fixed value to a variable value based on the patient's factor xa activity level. By measuring factor xa activity and adjusting the dosage accordingly (higher doses for severe deficiency, lower doses for mild deficiency), the treatment maintains simplicity while achieving reliable therapeutic efficacy across different patient populations.
2Reliability
If factor xa inhibitor is administered to achieve target factor xa activity levels, then therapeutic efficacy is improved, but risk of over-anticoagulation and bleeding increases
Solution Approach 1:
The patent implements a feedback mechanism where factor xa activity levels are measured before and after treatment, and the dosage is adjusted based on these measurements. This feedback loop ensures that the target factor xa activity level (30-70%) is achieved without excessive suppression, thereby reducing the risk of over-anticoagulation and bleeding while maintaining therapeutic efficacy.
3Reliability
If elevated factor xa activity is maintained to prevent thrombosis, then protective effect is improved, but risk of thrombosis with anticoagulant therapy increases
Solution Approach 1:
The patent applies dynamic adjustment of factor xa activity levels rather than maintaining a static elevated level. By individualizing the target activity level (30-70%) based on each patient's baseline factor xa activity and clinical condition, the treatment achieves adequate protection against thrombosis while minimizing the risk of thrombosis associated with over-anticoagulation.
Data Source
Figure 1
Figure 2
Figure 3\
AI summary
The present invention relates to a method of detecting Factor VIII level in a subject, particularly in a subject in need of treatment with at least one Factor Xa inhibitor. The method comprises (a) selecting at least one subject in need of treatment with at least one Factor Xa inhibitor; and (b) detecting Factor VIII level in a sample obtained from the at least one subject with the aim to determine an appropriate dosage of the at least one Factor Xa inhibitor. Preferably, the method comprises a further step of administering at least one Factor Xa inhibitor to the subject.